Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 176

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 2
Chunk 176
---
 $218,516 as compared to other expense for the three months
ended June 30, 2024 of $7,533. For the three months ended June 30, 2025, compared to the same period in 2024, this represented
a decrease of $210,983 or 2,801%. The other expense for the three months ended June 30, 2025 and 2024 was primarily the result
of an increased interest expense. The increase in the interest expense was due to the increased number and dollar amount of notes
held by the Company.

 Comparison
of the Six Months Ended June 30, 2025 and 2024

The
following table summarizes our results of operations for the six months ended June 30, 2025 and 2024:

    Six
    Months Ended June 30, 2025 and 2024

    2025

    2024

    $
    Change

    %
    Change

    OPERATING EXPENSES

    General and administrative expenses
     
    $
    2,200,133

    $
    1,997,435

    $
    202,698

    10
    %

    Research and development

    709,112

    479,561

    229,551

    48
    %

    Professional fees

    2,155,155

    1,221,072

    934,083

    76
    %

    Total operating expenses

    5,064,400

    3,698,068

    1,366,332

    37
    %

    Loss from operations

    (5,064,400
    )

    (3,698,068
    )

    (1,366,332
    ) 

    (37
    )%

    Other expense

    (352,150
    )

    (635,881
    )

    283,731

    45
    %

    Net loss before provision for income taxes

    (5,416,550
    )

    (4,333,949
    )

    (1,082,601
    ) 

    (25
    )%

    Provision for income taxes

    —

    —

    —

    NA

    Net loss
     
    $
    (5,416,550
    )

    (4,333,